ASX - Delayed Quote AUD

CSL Limited (CSL.AX)

281.80

+2.83

(+1.01%)

As of 11:11 AM GMT+10. Market Open.

CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?

CSL's (ASX:CSL) stock is up by 1.2% over the past month. We wonder if and what role the company's financials play in...

Simply Wall St. 21 days ago

CSL.AX
+1.01%
10 Best Long Term ASX Stocks To Invest In

In this piece, we will take a look at the ten best long term ASX stocks to invest in. If you want to skip our overview of the Australian stock market, then you can take a look at the 5 Best Long Term ASX Stocks To Invest In. Australia is one of the most prosperous […]

Insider Monkey 24 days ago

SKHHY

CSLLY

QBIEY
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure

CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III* 1 to improve exercise capacity.2 Ferinject has now received marketing authorization

CNW Group last month

CMXHF

CSLLY
CSL Ltd's Dividend Analysis

CSL Ltd (CSLLY) recently announced a dividend of $0.6 per share, payable on a date yet to be announced, with the ex-dividend date set for 2024-03-11. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into CSL Ltd's dividend performance and assess its sustainability.

GuruFocus.com last month

CSLLY
CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season

CSL Seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the trivalent strains recommended this week by the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC). During the meeting, the committee confirmed the viral strain selection of influenza vaccines for the Northern Hemisphere 2024/25 season, which aligns with the F

PR Newswire last month

CMXHF

CSLLY
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued

Key Insights Using the 2 Stage Free Cash Flow to Equity, CSL fair value estimate is AU$362 Current share price of...

Simply Wall St. last month

CSL.AX
+1.01%
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is based on pivotal Phase 3 PROTECT Study results European Commission decision is expected in Q2 2024 SAN DIEGO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor today announced that the European Medicines Agency’s (EMA) CHMP has recommended ap

GlobeNewswire last month

TVTX

CMXHF

CSLLY
Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

PR Newswire 2 months ago

CMXHF

CSLLY

CSL
CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI). The study did not meet its primary efficacy endpoint of MACE reduction at 90 days. As a result, there are no plans for a near-term regulatory filing. There wer

PR Newswire 2 months ago

CMXHF

CSLLY
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

KING OF PRUSSIA, Pa. & SAN DIEGO, February 05, 2024--Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the results of a follow-up analysis of a Phase 3 study evaluating a booster dose of ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, compared to a conventional mRNA COVID-19 vaccine. ARCT-154 was administered at one-sixth the dose of Comirnaty® (5 μg vs 30 μg, respectively).

Business Wire 2 months ago

ARCT

CMXHF

CSLLY
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

Here is how Cardinal Health (CAH) and CSL Limited Sponsored ADR (CSLLY) have performed compared to their sector so far this year.

Zacks 2 months ago

CAH

CSL.AX
+1.01%
CSL's (ASX:CSL) investors will be pleased with their decent 60% return over the last five years

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...

Simply Wall St. 2 months ago

CSL.AX
+1.01%
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options

CSL Behring, a business unit of global biotechnology leader CSL, today announced survey results showing that the majority of surveyed people living with chronic inflammatory demyelinating polyneuropathy (CIDP) agree they are interested in exploring more convenient treatment options (n=98, 82%) and that administering treatment at home is extremely/very important to them (n=100, 72%). However, less than half of people surveyed said they discuss potential new treatment options or switching treatmen

PR Newswire 3 months ago

CMXHF

CSLLY
CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe

CSL Behring, a business unit of global biotechnology leader CSL, today announced the availability of a 10g prefilled syringe for Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid). The Hizentra prefilled syringes provide people living with Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) the ability to elevate their treatment experience by eliminating the need to draw medication from vials. CSL Behring now has a wide range of prefilled syringe s

PR Newswire 3 months ago

CMXHF

CSLLY
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA (sa-mRNA) vaccine, elicited a numerically higher immune response (meeting the non-inferiority criteria) against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared

PR Newswire 4 months ago

ARCT

CMXHF

CSLLY
CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older

CSL Seqirus commends the National Advisory Committee on Immunization's (NACI's) recent recommendation for adults 65 years of age and older to preferentially receive an enhanced influenza vaccine, which includes adjuvanted, high-dose and recombinant vaccines. This recommendation is based on data from studies that show that all approved enhanced influenza vaccines are effective in reducing the risk of influenza-related hospitalization and medical encounters.

CNW Group 4 months ago

CMXHF

CSLLY
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application (BLA) for garadacimab (CSL312) as a once-monthly prophylactic treatment for hereditary angioedema (HAE). The company also announced the European Medicines Agency (EMA) has accepted the submission for CSL's Marketing Authorization Application (MAA) for garadacimab. If approved, garadacimab would become the first treatment for H

PR Newswire 4 months ago

CMXHF

CSLLY
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) today announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb) following a one-time infusion in people living with hemophilia B. The data showing that a one-time infusion of HEMGENIX offers elevated and sustained factor IX activity levels for years were presented in an oral presentation at the 65th American Society of Hematology (ASH) A

PR Newswire 4 months ago

CMXHF

CSLLY

QURE
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) granted approval for ARCT-154, a self-amplifying mRNA (sa-mRNA) COVID-19 vaccine for initial vaccination and booster for adults 18 years and older.

PR Newswire 4 months ago

ARCT

CMXHF

CSLLY
Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment

This Sunday, 26 November, marks Iron Deficiency Day, a day dedicated to raising awareness about the importance of diagnosing and treating iron deficiency and iron deficiency anemia. Supported by an alliance of international patient organizations and health advocacy groups, CSL Vifor takes a leading role annually to educate people about the importance of iron for the body and what can happen if iron levels are not properly managed. It encourages people to become better informed and to seek medica

CNW Group 4 months ago

CMXHF

CSLLY

Performance Overview

Return	CSL.AX	S&P/ASX 200 [XJO]
YTD	-1.07%	+1.70%
1-Year	-6.12%	+5.43%
3-Year	+6.86%	+9.34%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CSL Limited (CSL.AX)

CSL Limited (ASX:CSL) On An Uptrend: Could Fundamentals Be Driving The Stock?

10 Best Long Term ASX Stocks To Invest In

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure

CSL Ltd's Dividend Analysis

CSL Seqirus is Fully Prepared to Implement the FDA's Vaccines and Related Biological Products Advisory Committee Trivalent Influenza Vaccines Strain Selection for the 2024/25 U.S. Season

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])

New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

Are Medical Stocks Lagging Cardinal Health (CAH) This Year?

CSL's (ASX:CSL) investors will be pleased with their decent 60% return over the last five years

Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options

CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older

CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults

Iron Deficiency Day 2023: CSL Vifor calls for access to iron deficiency diagnosis and treatment

Performance Overview